GRI BIO INC

GRI Bio reveals promising Phase‑2a data for its NKT‑targeted antifibrotic GRI‑0621, showing improved lung function, biomarker reduction, and a strong safety profile for IPF patients.

GRI Bio Inc’s financial struggles and declining stock price raise concerns about its sustainability, despite its innovative approach to treating inflammatory diseases, and its future prospects depend on the success of its upcoming clinical trial.